A cartel between two Spanish pharmaceutical companies that were fined almost 6 million euros ($7.3 million) was uncovered by the national competition authority's in-house detection unit, according to the agency's boss. The source of the case is noteworthy because competition authorities across Europe — faced with falling leniency requests from cartelists —
* = Required Field
*Areas of Interest
MLex content is primarily organized into different areas of interest that cover the main elements of regulatory risk. Please indicate which ones you would like to be included in your Daily Wrap-up alert
MLex Limited and our LexisNexis Legal & Professional group of companies will use your personal information to administer your account and/or provide the products and services that you have requested from us. We may also contact you in your professional capacity with information about our other products, services and events that we believe may be of interest. You can manage your communication preferences via our Preference Center . You can learn more about how we handle your personal data and your rights by reviewing our Privacy Policy .
Nicholas covers EU merger review and antitrust investigations for Mlex in Brussels. He previously wrote about EU affairs for Politico Europe, European Voice and PaRR. After earning an LLM in European law from the College of Europe in Bruges, he spent a year working in the competition practice of a leading competition law firm in Brussels 2009-10. He graduated in modern European languages from Oxford University in 2006.